Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Companies

Set Alert for Companies

Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’

Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.

Companies Financing

Altimmune Regains Some Momentum

Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.

Clinical Trials Companies

Olema Boosts Its Partnering Position With SERD Combo Data

Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.

Clinical Trials Companies

Corporate VCs Play A Bigger Role In Hard Times

The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before.

Companies Financing

CAR-T Safety Probe Causes Alarm, But Is Unlikely To Upend Therapies

Hopes are that the impact of the US FDA’s investigation into a small number of T-cell malignancies associated with CAR-T therapies will be small since the benefit/risk profile still looks sound.

Drug Safety Cancer

Stock Watch: Is Oncology Still King?

Big pharmaceutical oncology franchise sales generally grew in the third quarter of 2023, but some were transitioning through loss of exclusivity and others were not being helped by their most innovative therapies.

Stock Watch Sales & Earnings

UK Biopharma Looks To Learn From Flagship Pioneering And Make ‘Bigger Leaps’

UK life sciences sector leaders are pleased to have attracted Flagship Pioneering to invest in the country, as its CEO Noubar Afeyan emphasizes that its initial focus would be on early ‘experiments’ in innovation and cultural bridge-building.

Commercial Companies

SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors

SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply. 

Approvals Launches

Chinese Domestic Alliances Focus On China-Only Rights As Confidence Grows

Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.

China Deals

BioCardia Aims To Defy Precedent With A Cardiac Cell Therapy

Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?

Clinical Trials Cardiovascular

Can GSK’s Blenrep Make A Comeback After Beating Darzalex? Eye Toxicity Concerns Remain

GSK will talk to regulators about bringing Blenrep back in earlier-stage myeloma patients, likely arguing that its convenience is greater than for CAR-T and carries a lower infection risk than bispecifics.

Clinical Trials Companies

Dupixent Heralds The Age Of Biologics In COPD

A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.

Clinical Trials Companies

As Biopharma Adopts Generative AI, The ‘People Element’ Is Crucial To Success

After a year of hype around generative AI, the question is can it deliver productivity wins for biopharma? Consultants at BCG give insights into successes and failures of early projects and emphasize that putting people first is key to success.

Commercial Clinical Trials

Syncona Buys Out Ailing Gene Therapy Company Freeline

Syncona has stepped in to save Freeline and give it more time to prove the value of FLT201, its early-stage Gaucher’s disease gene therapy.

Companies Financing

Flagship’s Latest Company To Search Somatic Genome To Find New Drugs

Quotient Therapeutics is the fifth new start-up unveiled by Flagship this year, and will be co-located in the US and UK to tap into leading academic genomic expertise.

StartUps and SMEs Companies

Mixed Q3 For China's Innovative Firms Amid Anti-Graft Campaign

China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.

China Sales & Earnings
See All
UsernamePublicRestriction

Register